• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Neuropathology . ApoE4 Homozygosity Is Associated With Increased Microglia Activation in Fatal COVID-19

tetano

Editor, Senior Moderator
Neuropathology


. 2025 Dec;45(6):e70033.
doi: 10.1111/neup.70033. ApoE4 Homozygosity Is Associated With Increased Microglia Activation in Fatal COVID-19

Amar Hamdan[SUP] 1 [/SUP], Yassir El-Amri[SUP] 1 [/SUP], Fabian Heinrich[SUP] 2 [/SUP], Osama A A Mohamed[SUP] 1 [/SUP], Diego Sepulveda-Falla[SUP] 1 [/SUP], Markus Glatzel[SUP] 1 [/SUP], Jakob Matschke[SUP] 1 [/SUP], Susanne Krasemann[SUP] 1 [/SUP]



Affiliations
Abstract

Apolipoprotein E4 (APOE4) is recognized as a major risk factor for disorders such as Alzheimer's disease and may play a role in the dysregulation of microglia in various neurodegenerative conditions. APOE variants have also been proposed as potential risk factors for severe outcomes in COVID-19. While fatal COVID-19 may be associated with increased neuroinflammatory changes especially in the brainstem, it is not fully understood whether APOE4 contributes to the latter. In this study, we determined the APOE genotype from archival paraffin tissue blocks of 38 patients with fatal COVID-19 who died either from infection with ancient SARS-CoV-2 or with the Omicron variant. Our data show an overrepresentation of APOE4 carriers during the first infection wave. Immunohistochemical staining of HLA-DR/DQ/DP was performed to determine the abundance of activated microglia in different brain regions. This analysis displayed a correlation of APOE4/E4 with increased microglial activation in the cerebellum in fatal COVID-19. Our data show a significant association between the APOE4 genotype and increased microglial activation, particularly affecting men who exhibit more microglial activity than women. In parallel, staining of SARS-CoV-2 nucleocapsid protein was used to assess the infection in the corresponding lung tissues. We found that a higher abundance of virus protein detection in the lungs was correlated with activation of microglia in the cerebellum in the latter cohort. Our work suggests that the cerebellum should be included when studying the impact of infectious diseases on the brain.

Keywords: APOE; COVID‐19; SARS‐CoV‐2; microglia; neuroinflammation; nucleocapsid.

 
Back
Top